Effect of Methylene blue oral rinse in treating pain related to cancer treatment in mouth

A Comparative study on assesing efficacy and safety of methylene blue oral rinse vs Standard therapy for treating pain from Oral Mucositis, related to cancer treatment in a tertiary care hospital-A Randomised Open labelled Prospective study. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/074782

Enrollment

Registered

2024-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K123- Oral mucositis (ulcerative)

Interventions

Intervention1: Methylene Blue Oral rinse(0.1%): One mouthful (5–10 mL) of Methylene blue solution(0.1%) and hold it at the painful sites for 5 min. To be used every 6hours for 2days duration Control I

Eligibility

Inclusion criteria

Inclusion criteria: clinically diagnosed with Oral mucositis receiving chemotherapy/Radiotherapy for malignancy

Exclusion criteria

Exclusion criteria: Patients with known history of hypersensitivity to methylene blue, pregnancy, breastfeeding mothers, cognitive impairment, not able to give consent, known documented history of G6PD deficiency, asymptomatic cases, pain due to oral ulcers /growth which are diagnosed to be malignancy

Design outcomes

Primary

Measure	Time frame
Numerical rating scale pain score will be assesedTimepoint: At baseline, day1 ,day 2	—

Secondary

Measure	Time frame
Oral functioning burden(OFB) will be assesedTimepoint: at baseline, day 1,day2	—

Countries

India

Contacts

Public ContactDr T Aruna

Tamilnadu Dr MGR Medical university

arunabala511@gmail.com9444276923

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026